Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase<scp>III DEFINE</scp>and<scp>CONFIRM</scp>studies - Concepedia

Concepedia

Publication | Open Access

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase<scp>III DEFINE</scp>and<scp>CONFIRM</scp>studies

DOI Full Paper Access

58

Citations

13

References

2017

Year

Eva Havrdová, Gavin Giovannoni, Ralf Gold, Robert Fox, Ludwig Kappos, J. Theodore Phillips, Macaulay Okwuokenye, Jing L. Marantz

European Journal of Neurology

Abstract

A significantly higher percentage of patients treated with DMF achieved NEDA status over 2 years compared with placebo.

References

	Year	Citations

Page 1